Stock CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Market Closed - Nyse
Other stock markets
 21:00:02 26/04/2024 BST 		5-day change 1st Jan Change
229 USD +0.54% Intraday chart for Charles River Laboratories International, Inc. +0.99% -3.12%
04-25 FibroBiologics, Inc. Plans to Collaborate with Charles River Laboratories to Manufacture Fibroblast-Based Spheroids CI
04-24 Charles River Laboratories Files Supplement to Definitive Proxy Statement with the Securities and Exchange Commission CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
FibroBiologics, Inc. Plans to Collaborate with Charles River Laboratories to Manufacture Fibroblast-Based Spheroids
Charles River Laboratories Files Supplement to Definitive Proxy Statement with the Securities and Exchange Commission
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
Charles River Laboratories International, Inc. and Deciphex Limited Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
Charles River Laboratories, Axovia Therapeutics Collaborate on Developing Rare Disease Gene Therapies
Charles River Laboratories International, Inc. Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
Charles River Laboratories Signs Plasmid DNA Manufacturing Deal With Ship of Theseus
Charles River Laboratories International, Inc. and Ship of Theseus Announces Good Manufacturing Practice Plasmid DNA Contract Development and Manufacturing Organization Agreement
Charles River Laboratories International, Inc Receives a Shareholder Proposal from People for the Ethical Treatment of Animals
Charles River Laboratories International, Inc. Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine
Charles River Laboratories International, Navega Therapeutics Partner for Production of AAV-Based Gene Therapy
Charles River Laboratories International, Inc. and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration
Charles River Laboratories International Insider Sold Shares Worth $959,545, According to a Recent SEC Filing
DURECT Corporation and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for Alzet® Product Line in U.S. and Canada
Charles River Laboratories International Insider Sold Shares Worth $1,268,500, According to a Recent SEC Filing
Charles River Laboratories International, Wheeler Bio Collaborate on Portable CMC Platform
Charles River Laboratories International Sets Accord With Wheeler Bio on Clinical Trials
Charles River Laboratories International, Inc. Announces Strategic Agreement with Wheeler Bio, Inc
Charles River Laboratories Q4 Non-GAAP Earnings, Revenue Fall
Charles River Laboratories International, Inc. Provides Financial Guidance for 2024
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRL Stock
  4. News Charles River Laboratories International, Inc.
  5. Other languages